The stock of Aeglea Biotherapeutics Incorporated (NASDAQ:AGLE) registered a decrease of 19% in short interest. AGLE’s total short interest was 34,100 shares in September as published by FINRA. Its down 19% from 42,100 shares, reported previously. With 41,900 shares average volume, it will take short sellers 1 days to cover their AGLE’s short positions. The short interest to Aeglea Biotherapeutics Incorporated’s float is 0.52%. About 21,746 shares traded hands. Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) has risen 6.00% since August 14, 2016 and is uptrending. It has underperformed by 10.49% the S&P500.
Aeglea BioTherapeutics, Inc. is a biotechnology company. The company has a market cap of $109.76 million. The Firm is engaged in the development of enzyme therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. It currently has negative earnings. The Company’s engineered human enzymes are designed to degrade specific amino acids in the blood.
Out of 4 analysts covering Aeglea BioTherapeutics (NASDAQ:AGLE), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aeglea BioTherapeutics has been the topic of 4 analyst reports since May 2, 2016 according to StockzIntelligence Inc. Needham initiated the stock on May 9 with “Buy” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.